MX2013002162A - Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina. - Google Patents

Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina.

Info

Publication number
MX2013002162A
MX2013002162A MX2013002162A MX2013002162A MX2013002162A MX 2013002162 A MX2013002162 A MX 2013002162A MX 2013002162 A MX2013002162 A MX 2013002162A MX 2013002162 A MX2013002162 A MX 2013002162A MX 2013002162 A MX2013002162 A MX 2013002162A
Authority
MX
Mexico
Prior art keywords
alcohol
dihydromyricetin
administration
methods
treating
Prior art date
Application number
MX2013002162A
Other languages
English (en)
Spanish (es)
Inventor
Jing Liang
Richard W Olsen
Igor Spigelman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2013002162A publication Critical patent/MX2013002162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2013002162A 2010-08-24 2011-08-23 Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina. MX2013002162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37652810P 2010-08-24 2010-08-24
PCT/US2011/048749 WO2012027326A2 (en) 2010-08-24 2011-08-23 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin

Publications (1)

Publication Number Publication Date
MX2013002162A true MX2013002162A (es) 2013-04-05

Family

ID=45724009

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002162A MX2013002162A (es) 2010-08-24 2011-08-23 Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina.

Country Status (14)

Country Link
US (1) US20130053435A1 (enExample)
EP (1) EP2608786A4 (enExample)
JP (1) JP2013536238A (enExample)
KR (1) KR20130098347A (enExample)
CN (1) CN103269699A (enExample)
AU (1) AU2011293556A1 (enExample)
BR (1) BR112013003946A2 (enExample)
CA (1) CA2808680A1 (enExample)
CL (1) CL2013000518A1 (enExample)
EA (1) EA201390217A1 (enExample)
MX (1) MX2013002162A (enExample)
PH (1) PH12013500293A1 (enExample)
SG (1) SG187771A1 (enExample)
WO (1) WO2012027326A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007853A1 (en) * 2012-07-03 2014-01-09 The Regents Of The University Of California Dihydromyricetin for the treatment of diseases and disorders of the glutamatergic system
CN103772338A (zh) * 2014-01-10 2014-05-07 吉首大学 真空脉动式制备二氢杨梅素的方法
EP3761979A4 (en) * 2018-04-06 2021-06-30 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT SUBSTANCE ABUSE
CN108567772A (zh) * 2018-07-24 2018-09-25 广西师范大学 二氢杨梅素的新用途
EP3876926A1 (de) * 2018-11-05 2021-09-15 Evanium Healthcare GmbH Alkohol-antidot
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
TW202110437A (zh) * 2019-05-23 2021-03-16 美商希諾瓦有限責任公司 用於酒精誘發之皮膚潮紅之治療及緩解的組成物及方法
MX2021015457A (es) 2019-06-14 2022-04-06 Univ Princeton Formulaciones de dihidromiricetina y un permeabilizante.
GR1010117B (el) 2020-07-14 2021-11-08 Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Διατροφικο συμπληρωμα για την απο του στοματος χορηγηση συνδυασμου διυδρομυρισετινης, χολινης και μιας ή περισσοτερων βιταμινων με αντιοξειδωτικη δραση, χρησιμων για τη φυσιολογικη λειτουργια του ηπατος
CN112546014B (zh) * 2020-12-15 2023-01-31 铜仁职业技术学院 一种中药解酒护肝泡腾片及其制备方法
CN118354770A (zh) * 2021-10-07 2024-07-16 罗特格斯新泽西州立大学 具有gabaa受体活性的类黄酮衍生物及使用方法
CN113842461B (zh) * 2021-11-04 2023-08-11 杭州诺莘科技有限责任公司 用于缓解、治疗酒精中毒、酒后不适的gabaa受体结合物、组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293825C (zh) * 2002-08-30 2007-01-10 广州拜迪生物医药有限公司 二氢杨梅树皮素在制备食品、化妆品或药品中的应用
KR20040021927A (ko) * 2002-09-06 2004-03-11 차재영 호깨나무와 홍삼 추출물을 이용한 건강 보조식품프로헤파-알지의 개발
CN101336978B (zh) * 2008-08-12 2013-01-30 西北农林科技大学 一种北枳椇总黄酮的提取方法
CN101336987B (zh) * 2008-08-12 2012-04-25 西北农林科技大学 一种枳椇总黄酮的制备方法

Also Published As

Publication number Publication date
BR112013003946A2 (pt) 2016-07-12
PH12013500293A1 (en) 2013-03-25
CA2808680A1 (en) 2012-03-01
KR20130098347A (ko) 2013-09-04
WO2012027326A9 (en) 2012-04-19
EA201390217A1 (ru) 2013-12-30
US20130053435A1 (en) 2013-02-28
EP2608786A2 (en) 2013-07-03
AU2011293556A1 (en) 2013-02-28
SG187771A1 (en) 2013-03-28
CN103269699A (zh) 2013-08-28
JP2013536238A (ja) 2013-09-19
CL2013000518A1 (es) 2013-08-02
WO2012027326A2 (en) 2012-03-01
EP2608786A4 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
PH12013500293A1 (en) Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
IN2014DN09434A (enExample)
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
BR112014026703A2 (pt) inibidores de dna-pk
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
PH12012501389A1 (en) Hedgehog inhibitors
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity

Legal Events

Date Code Title Description
FA Abandonment or withdrawal